Ekspresja kaspazy-3, Bax i Bcl-2 w łożyskach ciąż leczonych i nieleczonych z powodu wewnątrzmacicznego zahamowania wzrastania płodu by nawrocka-Kunecka, Agnieszka et al.
Nr 9/2009652
     
Ginekol Pol. 2009, 80, 652-656 
P R A C E  O R Y G I N A L N E
  p o ∏ o˝ni c two
 
Expression	of	caspase-3,	Bax	nad	Bcl-2	
in	placentas	from	pregnancies	complicated	by	
treated	and	non-treated	fetal	growth	restriction
Ekspresja kaspazy-3, Bax i Bcl-2 w Πo˝yskach cià˝ leczonych i nieleczonych 
z powodu wewnàtrzmacicznego zahamowania wzrastania pΠodu
Karowicz-Bilińska	Agata1,	Szczerba	Anita2,	Kowalska-Koprek	Urszula1,	
Nawrocka-Kunecka	Agnieszka,	Bartosz	Grzegorz3
1 High Risk Pregnancy Clinic Medical University Lodz
2 M. Kopernik Hospital Lodz 
3 Dept of Biophysics University Lodz 
 
 Abstract
Background: Fetal growth restriction (FGR) is the reason of high prematurity rate and its later complications. Re-
striction of utero-placental circulation, which could be changed by IURG treatment, plays the main role in FGR. The 
results of changes in apoptosis-related genes expression due to FGR treatment may help further in the prevention 
and treatment of FGR.
Material and methods: Caspase-3, Bax and Bcl-2 expressions in normal pregnancies and those complicated 
by treated and untreated FGR have been compared. The study was conducted in 2005-2006 at the High-Risk 
Pregnancy Unit of Medical University in Łódź and Kopernik Hospital in Łódź.
Caspase-3, Bax and Bcl-2 expressions were assessed by immunohistochemical method. Bcl-2 was assessed in 
the trophoblast, Bax and caspase-3 in the decidua and the trophoblast.
Results: The mean value of Bcl-2 in the trophoblast was 58.8±12.7 in the FGR-untreated group, 37.0±0.5 in the 
FGR-treated group and 65.7±6.9 in the control group. 
In the FGR-untreated group the mean value of Bax expression was 60.6±10.7 in the trophoblast and 32.0±7.3 in 
the decidua. In the FGR-treated group the mean value of Bax expression was 42.2±12.2 in the trophoblast and 
20.9±6.4 in the decidua. In the control group the mean value of Bax expression was 13.6±2.2 in the trophoblast 
and 6.6±6.8 in the decidua.
In the FGR-untreated group the mean value of Cpp-32 expression was 40.1±9.1 in the trophoblast and 42.6±.12.5 
in the decidua. In the FGR-treated group the mean value of Cpp-32 expression was 21.3±6.8 in the trophoblast and 
23.7±5.1 in the decidua. In the control group the mean value of Cpp-32 expression was 13,6±6,3 in trophoblast 
and 11.6±5.3 in the decidua.
Conclusions: Increased expression of pro-apoptotic proteins in the placenta might be one of the reasons for FGR 
development. The treatment used in the FGR group decreased the process of apoptosis.
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Introduction
	 Intrauterine	fetal	growth	restriction	(FGR)	means	a	newborn	
body	mass	less	than	the	10th	centile	with	respect	to	the	gestational	
age.	Early	and	precise	diagnosis	of	FGR	is	based	on	the	ultrasou-
nd	biometric	evaluation	of	the	fetus	compared	with	the	results	ob-
tained	in	the	early	pregnancy.	The	cases	that	started	early,	before	
the	24th	week	of	pregnancy,	are	more	serious,	with	less	favorable	
prognosis.	FGR	may	depend	on	various	reasons,	but	more	than	
80%	cases	of	FGR	of	unclear	origin	seem	to	be	connected	with	
changes	in	the	utero-placental	circulation	and	blood	vessels	mal-
function.	
	 There	 are	 many	 factors	 influencing	 the	 blood	 flow	 in	 the	
utero-placental	and	fetal	circulation,	chief	among	them	an	increa-
sed	activity	of	free	radicals.	An	increased	apoptosis	is	observed	in	
many	processes	connected	with	increased	free	radicals	activity.
	 In	our	previous	studies	on	free	radical	reactions	in	FGR	and	
normal	pregnancies	the	results	of	fetal	growth	and	Doppler	flows	
in	 the	umbilical	and	mild	cerebral	arteries	confirmed	 the	safety	
and	effectiveness	of	the	applied	pharmacological	treatment.
	 The	standard	treatment	of	ultrasound-diagnosed	FGR	in	the	
Clinic	of	High	Risk	Pregnancy	was	based	on	L-arginine	and	ace-
tylsalicylic	acid.
	 L-arginine	is	a	nitric	oxide	(NO)	precursor	which	has	a	strong	
diastolic	effect	on	the	vessels.	The	endothelial	nitric	oxide	syntha-
se,	the	content	of	the	e-NOS	enzyme,	is	thought	to	regulate	NO	
synthesis	in	blood	vessels	[1].
	 Acetylsalicylic	acid	affects	the	inhibition	of	the	thromboxane	
synthase,	and	by	this	decreases	the	synthesis	of	thromboxane.	The	
increase	of	prostacyclin	concentration	and	decrease	of	thrombo-
xane	 results	 in	 relaxation	of	 the	vessels,	 inhibits	 the	activity	of	
platelets	cyclooxygenase	and	has	an	anti-aggregative	effect	on	the	
platelets	and	improves	the	utero-placental	circulation.
	 Programmed	cell	death,	apoptosis,	which	determines	cell	de-
ath	is	regulated	by	independent,	multifactor,	often	contradictory	
processes	[2].	
	 In	the	group	of	Bcl	proteins	we	can	find	two	ways	of	action:	
pro-	 and	 anti-apoptotic.	Anti-apoptotic	 proteins	 of	Bcl-2	 group	
decrease	apoptosis	by	decreasing	cytochrome	C	release	and	blo-
cking	caspase-9	activity.	This	action	could	protect	mitochondrial	
membranes.	 Caspase-9	 is	 one	 of	 the	 enzymes	 from	 protease	
group,	initiating	apoptosis	-	cysteine	proteinase.	Initiating	factors	
and	specific	effectors	of	caspases	complex	compose	the	death	ini-
tiation	signaling	complex	(DISC).	
	 Bax,	 the	 protein	 from	 the	Bcl	 family,	 has	 a	 different,	 pro-
apoptotic	action.	It	is	activated	by		Bid	protein	and	decreases	mi-
tochondrial	membrane	permeability	[3].	
	 Caspase-3	–	CPP32,	apopain,	is	one	of	the	main	effectors	of	
apoptosis	 reactive	downstream	of	 caspase-9	apoptotic	pathway.	
In	cells	caspase-3	is	present	as	an	inactive	proenzyme	and	could	
be	activated	 	by	proteolytic	process	 to	 its	active	subunits	when	
cells	undergo	apoptosis.	Some	data	suggests	that	caspase-3	is	an	
important	mediator	of	apoptosis	in	the	immune	system	and	during	
the	morphogenetic	cell	death	in	the	mammalian	brain	[4,	5].
	 Increased	apoptosis	can	restrict	the	utero-placental	exchange	
and	affect	fetal	growth	restriction.	
Aim 
	 The	aim	of	this	study	was	to	find	the	difference	in	apoptotic	
activity	expressed	by	the	activity	of	caspase-3,	Bcl-2	and	Bax	in	
placentas	from	normal	pregnancies	and	from	those	complicated	by	
fetal	growth	restriction	–	both,	untreated	and	pharmacologically	
treated.	
 Streszczenie 
Hipotrofia wewnątrzmaciczna (FGR) wiąże się z wysokim odsetkiem wcześniactwa i jego późniejszych powikłań. W 
patogenezie hipotrofii główną rolę odgrywa ograniczenie przepływu maciczno-łożyskowego, co może być modyfi-
kowane przez stosowanie terapii. Uzyskanie zmian zachodzących  podczas leczenia w zakresie procesu apoptozy 
może wpłynąć w przyszłości na sposób zapobiegania i leczenia hipotrofii wewnątrzmacicznej. 
Materiał i metody: Porównano ekspresję kaspazy-3, Bax i Bcl-2 w ciąży niepowikłanej i powikłanej hipotrofią we-
wnątrzmaciczną z podziałem na kobiety nieleczone i leczone. Badania były prowadzone w Klinice Patologii Ciąży 
Uniwersytetu Medycznego w Łodzi w latach 2005-2006. Ekspresję  kaspazy-3, Bax i Bcl-2 oceniano metodami 
immunohistochemicznymi. Białko Bcl-2 było oceniane w trofoblaście, Bax i kaspaza-3 w doczesnej i trofoblaście. 
Wyniki: W grupie nieleczonych średnia wartość ekspresji Bcl-2 w trofoblaście wynosiła, 58,8±12,7, w grupie leczo-
nych 37,0±10,5, w grupie kontrolnej 65,7±6,9. W grupie nieleczonych średnia wartość Bax w trofoblaście wynosiła 
60,6±10,7, w doczesnej natomiast 32,0±7,3. W grupie kobiet leczonych średnia wartość ekspresji w trofoblaście 
wynosiła 42,2±12,2, w doczesnej natomiast 20,9±6,4. W grupie kontrolnej w trofoblaście wynosiła 13,6±2,2, a w 
doczesnej 6,6±6,8. W grupie nieleczonych średnia wartość kaspazy-3 mierzonej za pomocą aktywności Cpp-32 
wynosiła w trofoblaście 40,1±9,1, a w doczesnej 42,6±12,5. W grupie kobiet leczonych średnia ekspresja Cpp-32 
w trofoblaście wynosiła 21,3±6,8, w doczesnej 23,7±5,1. W grupie kontrolnej w trofoblaście wartość ekspresji Cpp-
32 oceniano na 13,6±6,3, w doczesnej uzyskano wartości 11,6±5,3.
Wnioski: Podwyższona ekspresja białek proapoptotycznych w łożysku może być jednym z powodów rozwoju 
hipotrofii wewnątrzmacicznej. Leczenie zastosowane w hipotrofii wewnątrzmacicznej obniżyło oceniane parametry 
apoptozy.
 Słowa kluczowe: apoptoza / kaspaza-3 / bax / bcl-2 / hipotrofia wewnątrzmaciczna /   
     / łożysko / leczenie / 
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Materials and Methods 
	 The	study	was	conducted	in	2006-2007	at	the	High	Risk	Pre-
gnancy	Clinic	of	Medical	University	of	Łódź.	A	written	informed	
consent	 of	 all	 subjects	 and	 the	 written	 approval	 of	 University	
Ethics	Committee	were	obtained.	
	 Three	groups	of	patients	were	compared:	1st	group:	pregnant	
women	in	pregnancy	complicated	by	fetal	growth	restriction	diag-
nosed	postnatally	–	the	weight	of	the	newborns	in	centile	charts	
9-5:	20	cases.	2nd	group:	pregnant	women	in	pregnancy	compli-
cated	by	fetal	growth	restriction	diagnosed	prenatally	-	treated	by	
L-arginine	and	acetylsalicylic	acid:	43	cases.	All	 cases	of	FGR	
were	 of	 unknown	 causes.	 3rd	 group:	 controls,	 pregnant	women	
with	normal	neonatal	weight:	15	cases.
	 2x2	excision	from	the	central	part	of	the	placenta,	near	the	
umbilical	cord	insertion,	was	taken	in	aseptic	conditions,	fixed	in	
the	formalin	solution	and	absorbed	in	paraffin	blocks.
	 Bcl-2,	anti-apoptotic	protein	was	assessed	by	an	immunohi-
stochemical	method	by	monoclonal	mouse	antibodies	anti	human	
Bcl-2	 oncoprotein.	 Bax	 rabbit	 anti	 human	 polyclonal	 antibody	
was	used	to	assess	Bax	activity.	To	evaluate	the	activity	of	caspa-
se-3	policlonal	rabbit	antibodies	anti	human	Cpp-32	protein	was	
used.	All	antibodies	were	produced	by	Dakocytomation.
	 Bcl-2	was	assessed	in	the	trophoblast.	The	assessment	of	Bax	
and	caspase-3	was	done	in	two	regions	of	placental	fragments:	the	
decidua	and	the	trophoblast.
	 A	 statistical	 analysis	 was	 done	 using	 non-parametric	 U–	
Mann	–Whitney	and	t-Student’s	tests.	p	value	<0.05	was	conside-
red	statistically	significant.
Results 
	 The	assessment	of	Bcl-2	was	done	in	the	trophoblast	by	co-
unting	brown	points	in	ten	random	zones	of	vision.	In	the	group	
of	untreated	intrauterine	growth	restriction	(20	cases),	the	lowest	
mean	expression	was	23.8	the	highest	53.7,	the	mean	expression	
of	Bcl-2	was	37.0±10.5.
	 In	the	group	of	intrauterine	growth	restriction	treated	by	L-ar-
ginine	the	evaluation	was	done	in	43	fragments.	The	lowest	mean	
expression	of	Bcl-2	was	30.0,		the	highest	73.7	and	the	mean	va-
lue	was	58.8±12.7.	In	the	control	group	the	evaluation	of	Bcl-2	
value	was	done	in	15	fragments	of	placentas	in	ten	random	zo-
nes	of	vision.	The	lowest	mean	expression	of	Bcl-2	was	53.7,	the	
highest	75.7	and	the	mean	value	was	65.74±6.9.	(Table	I).
	 In	a	group	of	healthy	mothers	of	normal-weight	newborns	the	
expression	of	Bcl-2	was	higher	than	in	both	FGR	groups.	In	the	
FGR-untreated	group		it	was	lower	than	in	the	FGR-treated	group.	
The	difference	between	Bcl-2	expression	in	the	compared	groups	
was	statistically	significant	(p<0.05).
	 The	evaluation	of	Bax	was	done	in	the	trophoblast	and	the	de-
cidua	separately,	by	counting	brown	points	in	ten	and	six	random	
zones	of	vision	respectively.	The	lowest	mean	expression	of	Bax	
in	FGR-untreated	group	in	the	trophoblast	was	28.0,	the	highest	
was	70.1,	the	mean	value	was	60.57±10.73.	In	the	FGR-treated	
group,	the	lowest	mean	expression	of	Bax	in	the	trophoblast	was	
23.5,	the	highest	was	68.8	and	the	mean	value	was	42.2±12.2.	In	
the	control	group	in	the	trophoblast	the	lowest	mean	expression	of	
Bax	was	10,4,	the	highest	was	16,3,	the	mean	value	was	13.6±2.2.	
(Table	II).
	 In	 a	 group	of	 healthy	mothers	 of	 normal-weight	 newborns	
the	expression	of	Bax	in	the	trophoblast	was	lower	than	in	both	
FGR	groups.	In	the	FGR-untreated	group	the	expression	of	Bax	
was	higher	than	in	group	of	pharmacologically	treated	FGR.	The	
difference	between	Bax	expression	in	the	trophoblast	in	the	com-
pared	groups	was	statistically	significant	(p<0.05).
	 In	 the	 decidual	 part	 of	 the	 placenta	 in	 the	 FGR-untreated	
group	the	lowest	mean	expression	of	Bax	was	20.0,	the	highest	
was	45.5	and	the	mean	value	was	32.0±7.3.	In	the	FGR-treated	
group	the	lowest	mean	expression	of	Bax	was	9.8,	the	highest	was	
40.7	and	the	mean	value	was	20.9±6.4.	In	the	control	group	the	
lowest	mean	expression	of	Bax	was	2.3,	the	highest	was	24.0	and	
the	mean	value	was	6.6±6.8.	(Table	III).	
	 In	both	areas,	the	trophoblast	and	the	deciduas,	the	expres-
sion	of	Bax	was	significantly	higher	in	the	placentas	from	FGR	
–complicated	pregnancies	than	in	the	control	group	(p<0.05).
	 Caspase-3	measurement	showed	as	Cpp-32	expression	was	
done	in	two	regions:	the	trophoblast	and	the	decidua.	
	 In	the	FGR-untreated	group	the	lowest	mean	expression	of	
Cpp-32	in	the	trophoblast	was	29.0	the	highest	was	59.5,	the	mean	
value	was	40.1±9.1.	In	the	group	of	intrauterine	growth	restriction	
treated	by	L-arginine	the	lowest	mean	expression	of	Cpp-32	was	
12.8,	the	highest	was	39.8	and	the	mean	value	was	21.3±6.8.	
	 In	the	control	group	the	lowest	mean	expression	of	Cpp-32	
was	7.0,	the	highest	was	25.6	and	the	mean	value	was	13.6±6.3.	
(Table	IV).
	 In	the	FGR-untreated	group	the	lowest	mean	expression	of	
Cpp-32	 in	 the	 decidua	was	 17.5,	 the	 highest	was	 65.5	 and	 the	
mean	value	was	42.6±12.5.	 In	 the	group	of	 intrauterine	growth	
restriction	 treated	by	L-arginine	 the	 lowest	mean	expression	of	
Cpp-32	was	12,2,	the	highest	was	30.5	and	the	mean	value	was	
23.7±5.1.
	 In	the	control	group	the	lowest	mean	expression	of	Cpp-32	
was	4.3,	the	highest	was	20.8	and	the	mean	value	was	11.6±5.3.	
In	the	control	group	the	expression	of	Cpp-32	was	higher	than	in	
both	FGR	groups.	In	the	FGR-untreated	group	the	expression	of	
Cpp-32	was	 lower	 than	 in	 the	FGR-treated	one.	The	difference	
between	Cpp-32	expression	in	every	compared	group	was	statisti-
cally	significant	(p<0.05).	(Table	V).
Discussion
 In	 our	 study	 the	 etiology	 of	 FGR	was	 unknown	 and	 such	
inductive	 factors	 as	 cigarette	 smoking,	 hypertension,	 genetic	
disorders,	 infections	 in	 early	 pregnancy,	 cholestasis,	 heart	 and	
urinal	 tract	diseases	were	excluded,	owing	to	which	our	groups	
of	 patients	were	 very	 similar.	 In	many	 studies	 on	 fetal	 growth	
restriction	those	factors	were	present	and	could	have	changed	the	
results.
	 The	 treatment	used	 in	our	study	makes	significant	changes	
on	values	of	selected	pro-	and	anti-apoptotic	factors	in	the	group	
of	FGR	mothers.	As	we	observed,	the	treatment	of	FGR	decreases	
metabolites	of	free	radicals	reactions.	Those	metabolites,	which	
have	 restrictive	 action	 on	 blood	 vessels,	 cause	 the	 decrease	 of	
mother-to-fetus	 exchange	 and	 may	 initiate	 FGR	 in	 pregnancy.	
An	 improvement	 of	 blood	 circulation	 leads	 to	 the	 decrease	
of	 free	 radicals	 reactions	 and	 to	 the	 reduction	 of	 small	 vessels	
restriction.
	 Some	of	the	parameters	of	lipid	peroxidation	process	cause	
destruction	 of	 the	 mitochondrial	 membranes	 in	 the	 central	
nervous	 system	 and	 of	 other	 tissues,	 what	 can	 also	 cause	 cell	
destabilization.	
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Table I. Bcl-2 expression in the trophoblast in the compared groups (values from 10 zones of vision). 
 
Table II. Bax expression in the trophoblast in the compared groups. 
 
Table III. Bax expression in decidua in compared groups.  
 
Table IV. Cpp-32 expression in the trophoblast in the compared groups. 
 
Table V. Cpp-32 expression in the decidua in the compared groups. 
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	 The	 results	 of	 L-arginine	 treatment	 show	 the	 decrease	 of	
elevated	concentrations	of	HNE	in	the	group	of	FGR	pregnancies	
after	the	applied	treatment.	HNE,	one	of	the	toxic	products	of	li-
pid	peroxidation,	is	also	involved	in	the	modification	of	Cyt	C	and	
activity	of	capases-system	in	the	process	of	apoptosis.	Increased	
concentration	of	HNE	can	also	cause	DNA	fragmentation	and	be	
the	reason	of	increased	apoptosis	[7].
	 In	both	groups	of	pregnancies	complicated	by	fetal	growth	
restriction	we	 found	higher	 expression	of	Bax	 than	 in	 the	 con-
trol	 group,	 that	means	 higher	 activity	 of	 the	 apoptotic	 process.	
The	importance	of	apoptosis	cascade	for	the	normal	function	of	
the	 trophoblast	 is	 a	well-known	 fact.	Apoptotic	 changes	 in	 the	
trophoblast	have	been	described	 in	many	complications	of	pre-
gnancy	[8].	
	 In	our	study	 in	 the	decidual	part	of	 the	placenta,	apoptosis	
seems	to	be	higher	in	the	group	of	fetal	growth	restriction	than	in	
placentas	from	the	control	group,	which	is	similar	to	the	results	of	
other	authors	[7].	
	 Some	of	 the	pro-apoptotic	proteins	are	highly	expressed	 in	
human	placenta	with	placental	dysfunction	as	hypoxia	and	fetal	
growth	restriction.	It	has	been	stated	that	placental	hypoxia	causes	
an	increase	of	apoptosis,	that	could	be	the	unknown,	early	factor	
for	intrauterine	growth	restriction	[8].	The	changes	in	regulation	
of	apoptosis	in	the	extravillous	trophoblast	could	cause	restriction	
of	blood	flow	and	decrease	the	maternal-fetal	circulation	[4].	
	 An	 increased	 apoptosis	 in	 spiral	 arteries	 that	 limits	 the	
trophoblast	invasion	into	the	decidua		could	be	the	reason	for	hy-
pertension	in	pregnancy	and	FGR	[6].	The	trophoblast	cells	su-
sceptibility	to	undergo	apoptosis	determines	the	apoptosis	of	the	
endovascular	trophoblast	and	probably	influences	the	transforma-
tion	of	the	uterine	spiral	arteries	[10].
	 We	 found	high	expression	of	Bax	and	 low	of	Bcl-2	 in	 the	
extravillous	trophoblast,	what	is	similar	to	the	results	obtained	by	
Huppertz	[5]	and	could	be	responsible	for	the	malfunction	of	the	
vessels.
	 Our	 results	 are	 in	 disagreement	 with	 the	 observations	 of	
Endo,	who	found	no	significant	difference	in	Bax	expression	in	
the	normal	and	FGR	placentas	[9].	In	our	study	in	both	regions,	
the	 trophoblast	 and	 the	decidua,	 the	expression	of	Bax	 in	FGR	
group	was	higher	than	in	the	control	group.	High	Bax	expression	
showed	in	our	study	points	to	the	role	of	increased	apoptosis	in	
placentas	from	fetal	growth	restriction.
	 The	 analysis	 of	 presence	 of	 apoptotic	 cells	 done	 in	 fetal	
membranes	showed	the	increase	of	apoptosis	in	FGR	group	when	
compared	to	normal	pregnancy	[11].	
	 In	fetal	growth	restriction	the	density	of	microvilli	was	redu-
ced	and	the	basal	membrane	was	thicker	in	FGR	than	in	normal	
growth,	 what	 means	 that	 increased	 apoptosis	 in	 the	 syncytio-
trophoblast	which	could	cause	growth	restriction	by	cell	deletion	
[12].	Our	data	show	higher	expression	of	estimated	pro-apoptotic	
factors	in	both	regions,	the	trophoblast	and	the	decidua,	in	FGR	
group,	what	is	similar	to	the	observations	of	other	authors	[9,	10,	
11,	12].
	 Immunohistochemical	 analysis	 shows	 significantly	 higher	
expression	of	the	active	form	of	caspase-3	in	FGR	than	in	a	nor-
mal	pregnancy	in	data	presented	by	Endo	[9].
	 Our	study	shows	similar	 results	of	caspase-3	expression	 in	
both	 regions	 of	 placenta,	 the	 trophoblast	 and	 the	 deciduas.	We	
have	observed	the	highest	expression	of	caspase-3	in	the	group	of	
untreated	fetal	growth	restriction,	lowering	due	to	the	L-arginine	
treatment.	The	lowest	expression	of	caspase-3	was	observed	in	the	
control	group.	This	observation	suggests	 that	apoptosis	 through	
activation	caspase-3	may	play	a	role	in	FGR.
	 In	our	study	one	of	the	FGR	therapy	elements	was	acetylsali-
cylic	acid	and	the	results	showing	low	expression	of	pro-apoptotic	
parameters	in	the	FGR-treated	group	could	be	related	not	only	to	
L-arginine	but	also	to	acetylsalicylic	acid	action.
	 Hills	suggests	 the	ability	of	another	anticoagulant,	heparin,	
to	 antagonize	 cell	 death	 process	 by	 activation	of	multiple	 anti-
apoptotic	 pathways	 in	 the	 placenta	 to	 be	 potentially	 useful	
in	 the	 management	 of	 at-risk	 patients,	 even	 in	 the	 absence	 of	
thrombophilic	disorder	[13].
	 In	the	placentas	of	smoking	mothers	with	growth-restricted	
infants	apoptosis	was	also	increased.	The	reduction	in	blood	flow	
could	also	increase	apoptosis,	and	it	is	possible	that	this	could	be	
one	of	the	mechanisms	playing	a	role	in	the	growth	restriction.	In	
our	study	all	pregnant	women	were	non-smokers	and	the	changes	
in	 the	expression	of	pro-apoptotic	factors	observed	in	placentas	
were	similar	[14].
Conclusions
1.	 Increased	expression	of	pro-apoptotic	proteins	in	the	placenta	
might	be	one	of	the	reasons	for	FGR	development.
2.	 The	treatment	used	in	the	FGR	group	decreased	the	process	of	
apoptosis.
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